Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful?

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Platelet activation is key in acute coronary syndromes (ACS), including stent thrombosis and myocardial infarction.
• Aspirin plus P2Y12-inhibitors are standard for ACS treatment and prevention post-intervention.
• Extended P2Y12-inhibitor therapy is considered due to ongoing ischemic risk after standard treatment durations.

Purpose of the Study:

• To review the benefits and risks of prolonged P2Y12-inhibitor treatment.
• To focus on ticagrelor's role in extended therapy for myocardial infarction patients.
• To identify patient subgroups who may benefit from extended treatment.

Main Methods:

• Literature review of studies on P2Y12-inhibitor therapy duration.
• Analysis of clinical trial data regarding efficacy and safety.
• Focus on evidence related to ticagrelor in post-myocardial infarction settings.

Main Results:

• Extended P2Y12-inhibitor use can decrease recurrent ischemic events.
• Increased bleeding risk is a significant limitation of prolonged therapy.
• Optimal patient selection for extended treatment remains challenging.

Conclusions:

• Prolonged P2Y12-inhibitor therapy requires careful risk-benefit assessment.
• Ticagrelor shows promise for extended use, particularly post-myocardial infarction.
• Further research is needed to define criteria for selecting patients for long-term treatment.